These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 37278280)

  • 21. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
    Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
    J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Felix M; Friedel D; Jayavelu AK; Filipski K; Reinhardt A; Warnken U; Stichel D; Schrimpf D; Korshunov A; Wang Y; Kessler T; Etminan N; Unterberg A; Herold-Mende C; Heikaus L; Sahm F; Wick W; Harter PN; von Deimling A; Reuss DE
    Neuro Oncol; 2022 Dec; 24(12):2121-2132. PubMed ID: 35511748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
    Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
    Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
    Shao LW; Pan Y; Qi XL; Li YX; Ma XL; Yi WN; Zhang J; Zhong YF; Chang Q
    Histol Histopathol; 2016 Jan; 31(1):103-14. PubMed ID: 26395639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
    Komori T
    Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 28. Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas.
    Zepeda-Mendoza CJ; Vaubel RA; Zarei S; Ida CM; Matthews M; Acree S; Raghunathan A; Giannini C; Jenkins RB
    Acta Neuropathol; 2020 Jun; 139(6):1105-1107. PubMed ID: 32170402
    [No Abstract]   [Full Text] [Related]  

  • 29. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
    Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
    Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
    Santosh V; Rao S
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S14-S23. PubMed ID: 35562130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
    Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
    Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study.
    Anand N; Husain N; Varshney R; Malhotra KP; Kaif M
    J Carcinog; 2021; 20():20. PubMed ID: 34729052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
    Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
    J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of targeted next-generation sequencing assay to detect 1p/19q co-deletion in formalin-fixed paraffin-embedded glioma specimens.
    Pallavajjala A; Haley L; Stinnett V; Adams E; Pallavajjala R; Huang J; Morsberger L; Hardy M; Long P; Gocke CD; Eshleman JR; Rodriguez FJ; Zou YS
    Hum Pathol; 2022 Aug; 126():63-76. PubMed ID: 35561840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas.
    Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M
    Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.